16 results about "Ghrelin" patented technology

The invention relates to the technical field of medicines, in particular to application of a growth hormone releasing peptide Ghrelin receptor in itching intervention. By adjusting the activity of the receptor, the invention provides a new strategy for intervening pruritus: activation of the Ghrelin receptor can be used for inducing pruritus so as to construct a disease model; and inhibiting the Ghrelin receptor is used for preventing or treating pruritus, and the pruritus comprises acute pruritus and chronic pruritus. In specific implementation, the inhibition of the receptor is realized by applying the Ghrelin receptor antagonist, and the activation of the receptor is realized by applying the Ghrelin receptor agonist. Therefore, by targeting the Ghrelin receptor, controllable induction and efficient inhibition of pruritus are realized, mechanism innovation, treatment practicability and conversion feasibility are integrated, and a breakthrough strategy is provided for prevention and treatment of pruritus-related diseases.

Compositions and methods are provided for inactivating ghrelin in mammalian cells by administration of a polynucleotide encoding a butyrylcholinesterase (BChE) enzyme. The compositions and methods disclosed herein may be administered to mammals or mammalian cells for reducing drug-seeking behavior.

The present application provides a biological product and a method and an application thereof. The biological product is used for the preparation of a therapeutic agent for cancer treatment, and it includes at least one of the recombinant butyrylcholinesterase-albumin (rBChE-albumin) fusion protein and the recombinant butyrylcholinesterase-Fc (rBChE-Fc) fusion protein. The biological product adjusts the balance of acetylcholine and other related metabolic pathways by supplementing at least one of the exogenous rBChE-albumin fusion protein and rBChE-Fc fusion protein to treat cancer. The present invention solves the problem that the extraction and purification of BChE from human serum may not meet the huge demand for cancer treatment. The present application further provides a biological product for neutralizing and degrading nerve agents and organophosphate compounds, hydrolyzing ghrelin, and anti-wrinkle.

This invention belongs to the field of biomedical technology and discloses a specific structural lipase inhibitor that promotes ATGL activation, its preparation method, and its application. The inhibitor is derived from grape leaves. Through optimized extraction processes, the lipase inhibitory activity is significantly improved. The compound composition and structural ratio of the inhibitor are directionally enriched and clarified, resulting in a product with stable activity and controllable quality. Experiments have confirmed that the lipase inhibitor described in this application can simultaneously inhibit fat absorption and activate ATGL, forming a dual mechanism of action of "inhibiting absorption" and "inhibiting storage." It reduces TG, TC, LDL-C, LP, and FFA, upregulates HDL-C, stabilizes leptin, reduces ghrelin, and increases CCK and PYY, thereby effectively regulating lipid metabolism, controlling weight, improving blood lipids, and stabilizing blood sugar, with high safety.

The present invention relates to compounds of general formula (I), wherein the groups R1, R2 and n are defined as in claim 1, which are ghrelin O-acyl transferase (GOAT) inhibitors for use in the treatment of substance use disorder (SUD,) in particular for use in the treatment of opioid use disorder (OUD) or stimulant use disorder (StimUD), in patients with high impulsivity.

The present invention relates to a use of a triazole compound as a ghrelin receptor agonist and, more specifically, to a composition for preventing or treating diseases mediated by the ghrelin receptor, the composition being of a triazole compound which strongly binds to the ghrelin receptor with very high specificity. The compound provided by the present invention exhibits a strong binding force to the ghrelin receptor with very high specificity, and thus may be very usefully employed for preventing or developing a therapeutic agent for diseases mediated by the ghrelin receptor.

Compositions and methods are provided for inactivating ghrelin in mammalian cells by administration of a polynucleotide encoding a butyrylcholinesterase (BChE) enzyme.

Disclosed are methods for mitigating one or more debilitating symptoms of a mTBI for a patient diagnosed with mTBI, e.g. sustained mTBI. These methods comprise administering an effective amount of ghrelin or a variant thereof over multiple consecutive days after the diagnosis of a mTBI, e.g. sustained mTBI.

The novel compound 3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea monohydrochloride has high permeability, is able to cross the blood-brain barrier and shows consistent ghrelin agonist activity at the level of the central nervous system; the compound is effective in the treatment and / or prevention of medical conditions mediated by ghrelin receptors in the central nervous system. In particular, in experimental tests, the compound shows high efficacy in the treatment of neurotoxic injuries and has an effective neuroprotective action combination pattern at both central and peripheral levels. The compound is also useful in the treatment of diseases requiring a reduction in heart rate. The compound has pharmacological activity at low to moderate doses, thus showing a good therapeutic index.

The present application belongs to the technical field of biomarkers, and particularly relates to a system for evaluating the effectiveness of exercise intervention and application thereof. The present application finds through experiments that the Lac-Phe level in the stomach of obese patients is significantly reduced after exercise intervention, and other tissues have no significant change. Considering the role of the stomach in endocrine signal transduction, especially through ghrelin and other appetite-related hormones, this indicates that there is a potential interaction between Lac-Phe and the stomach pathway in regulating post-exercise satiety. Therefore, the expression level of Lac-Phe in the stomach tissue can be used as an effective index for evaluating the weight loss effect of exercise on obese patients.

The present invention relates to a pharmaceutical composition for preventing, ameliorating, or treating anorexia and weight loss, comprising a Bupleuri Radix extract. Specifically, the present invention provides a pharmaceutical composition having effects in preventing, ameliorating, or treating anorexia and weight loss, wherein a Bupleuri Radix extract increases ghrilin, which is a hormone that stimulates appetite, and decreases TPH1(I), which is a serotonin synthase. In addition, a health functional food for preventing or ameliorating anorexia and weight loss, comprising a Bupleuri Radix extract, can be developed, and the extract can be effectively used for the treatment and the development of therapeutic agents for anorexia induced by chemotherapy in the future.

This invention relates to the delivery of a composition, preferably a pharmaceutical composition, comprising D-pinitol, D-Chiro inositol or myo-inositol or any pharmaceutically acceptable salt thereof, for use in the treatment or prevention of disorders, diseases or conditions responsive to the stimulation of the ghrelin receptor in a subject in need thereof. In particular, for the treatment and / or prevention of disorders responsive to the positive modulation (stimulation) of the ghrelin receptor, such as diabetes, obesity-related disorders, and, most preferably, for treating or preventing age related conditions or diseases such as by promoting appetite, inhibiting insulin secretion and lowering insulin resistance, increasing growth hormone release, enhancing muscle vitality or fragility and treating or preventing sarcopenia by increasing net muscle mass, improving cognition (and / or treating or preventing diseases such as Azlheimer's disease, vascular dementia, Parkinson's Disease, and Huntington's disease) and treating or preventing age related hypertension.

The present invention relates to compounds of general formula I,wherein the groups R1, R2 and n are defined herein, which are ghrelin O-acyl transferase (GOAT) inhibitors. The invention also relates to the use of compounds of formula (I) for treatment of substance use disorder (SUD,) in particular for use in the treatment of opioid use disorder (OUD) or stimulant use disorder (StimUD), in patients with high impulsivity.

Compositions and methods are provided for inactivating ghrelin in mammalian cells by administration of a polynucleotide encoding a butyrylcholinesterase (BChE) enzyme.

Methods for preventing or treating brain neuronal diseases are provided. The methods include administering mesenchymal stem cells having increased agouti-related peptide (AgRP) expression or a conditioned medium thereof to a subject in need thereof. In some embodiments, the conditioned medium contains AgRP. The methods may further comprise administering ghrelin. The brain neuronal diseases include Alzheimer's disease, frontotemporal dementia, tauopathy, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, stroke, thrombosis, embolism, head trauma, cerebral circulatory or metabolic disorders, brain dysfunction, and dementia.